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ABSTRACT
Hirschsprung disease (HSCR, aganglionic megacolon)
represents the main genetic cause of functional intestinal
obstruction with an incidence of 1/5000 live births. This
developmental disorder is a neurocristopathy and is
characterised by the absence of the enteric ganglia along
a variable length of the intestine. In the last decades, the
development of surgical approaches has importantly
decreased mortality and morbidity which allowed the
emergence of familial cases. Isolated HSCR appears to be
a non-Mendelian malformation with low, sex-dependent
penetrance, and variable expression according to the
length of the aganglionic segment. While all Mendelian
modes of inheritance have been described in syndromic
HSCR, isolated HSCR stands as a model for genetic
disorders with complex patterns of inheritance. The
tyrosine kinase receptor RET is the major gene with both
rare coding sequence mutations and/or a frequent variant
located in an enhancer element predisposing to the
disease. Hitherto, 10 genes and five loci have been found
to be involved in HSCR development.
Harald Hirschsprung, a Danish paediatrician, first
described in 1888 two unrelated boys who died
from chronic severe constipation with abdominal
distension resulting in congenital megacolon.1 The
absence of intramural ganglion cells of the myen-
teric and submucosal plexuses (Auerbach and
Meissner plexuses, respectively) downstream of
the dilated part of the colon was recognised as the
cause of the disease in the 1940s.2 This allowed a
simple and reliable diagnostic confirmation from
rectal suction biopsies using histochemical staining
for acetylcholinesterase (AchE).3 In 1948, Swenson
and Bill developed a surgical procedure4 and the
survival of patients uncovered familial transmis-
sion of Hirschsprung disease (HSCR).5 In 1974,
Bolande proposed the term neurocristopathy for
syndromes or tumours involving the neural crest
(NC) cells.6 HSCR resulting from an anomaly of
the enteric nervous system (ENS) of NC origin is
therefore regarded as a neurocristopathy.6–8
Isolated HSCR appears to be of complex, non-
Mendelian inheritance with low, sex-dependent
penetrance, variable expression according to the
length of the aganglionic segment and suggestive
of the involvement of one or more gene(s) with
low penetrance.5 9 These parameters must be taken
into account for accurate evaluation of recurrence
risk in relatives. With a relative risk as high as 200,
HSCR appears an excellent model to study
common multifactorial diseases. The major sus-
ceptibility gene is RET, which is also involved in
multiple endocrine neoplasia type 2 (MEN 2) and
familial medullary thyroid carcinoma (FMTC).
Coding sequence mutations are identified in about
50% and 15% of familial and sporadic HSCR cases,
respectively. The far most frequent HSCR predis-
posing event at the RET locus is a haplotype which
comprises an SNP lying in an enhancer element of
RET intron 1. The identification of modifier genes
is currently underway by using various approaches
and an international consortium has been settled
in 2004 in order to achieve this goal.
HSCR occurs as an isolated trait in 70% of
patients, is associated with a chromosomal
abnormality in 12% of the cases, and with
additional congenital anomalies in 18% of the
cases.10–15 In the latter group of patients, some
monogenic syndromes can be recognised. Indeed,
thus far, genetic heterogeneity in HSCR has been
demonstrated with 10 specific genes involved. The
aim of this paper is to update a 6 year old review
on clinical and molecular data about isolated and
syndromic HSCR.
DEFINITION AND CLASSIFICATION
HSCR is a congenital malformation of the hindgut
characterised by the absence of parasympathetic
intrinsic ganglion cells in the submucosal and
myenteric plexuses.2 It is regarded as the conse-
quence of the premature arrest of the craniocaudal
migration of vagal neural crest cells in the hindgut
between the fifth and 12th week of gestation to
form the enteric nervous system (ENS) and is
therefore regarded as a neurocristopathy.6 16 While
the internal anal sphincter is the constant inferior
limit, patients could be classified as short-segment
HSCR (S-HSCR: 80% of cases) when the aganglio-
nic segment does not extend beyond the upper
sigmoid, and long-segment HSCR (L-HSCR: 20%
of cases) when aganglionosis extends proximal to
the sigmoid. Four HSCR variants have been
reported: (1) total colonic aganglionosis (TCA, 3–
8% of cases)17; (2) total intestinal HSCR when the
whole bowel is involved17; (3) ultra-short segment
HSCR involving the distal rectum below the pelvic
floor and the anus18; (4) suspended HSCR, a
controversial condition, where a portion of the
colon is aganglionic above a normal distal segment.
Review
J Med Genet 2008;45:1–14. doi:10.1136/jmg.2007.053959 1
 on 20 May 2009 jmg.bmj.comDownloaded from 
CLINICAL FEATURES AND DIAGNOSIS
In most cases, the diagnosis of HSCR is made in the newborn
period15 due to intestinal obstruction with the following
features: (1) delayed of passage of meconium (.24 h after
birth); (2) abdominal distension that is relieved by rectal
stimulation or enemas; (3) vomiting; and (4) neonatal entero-
colitis. Some patients are diagnosed later in infancy or in
adulthood with severe constipation, chronic abdominal disten-
sion, vomiting, and failure to thrive.19 Finally, although a rare
presentation, unexplained perforation of the caecum or appen-
dix should make the diagnosis considered.
On abdominal x ray a distended small bowel and proximal
colon, with absence of rectal gas, are common findings. The
classical image is a dilated proximal colon with the aganglionic
cone narrowing towards the distal gut. On barium enema a
small rectum with uncoordinated contractions is seen. The
transitional zone represents the site where the narrow
aganglionic bowel joins the dilated ganglionic bowel. On a
delayed plain x ray taken 24 h after the enema, barium retention
is observed. Anorectal manometry shows absence of relaxation
of the internal sphincter (rectal inhibitory reflex) in response to
rectal distension.20 The reliability of this test becomes excellent
from day 12 after birth where the normal rectoenteric reflex is
present.21 Suction rectal biopsy remains the gold standard for
confirming the diagnosis in most cases demonstrating an
increased acetyl cholinesterase activity.22 Nonetheless, full
thickness rectal biopsy is the golden standard in reaching the
diagnosis. Furthermore, seromuscular biopsies will be needed at
operation to define the proximal limit of the aganglionic
segment.
DIFFERENTIAL DIAGNOSES
Other causes of intestinal obstruction should be discussed when
abdominal distension and failure to pass meconium occur in a
newborn infant: (1) meconium ileus resulting from cystic
fibrosis; (2) intestinal malformations such as lower ileal and
colonic atresia, isolated or occasionally associated with HSCR,
intestinal malrotation or duplication; (3) ENS anomalies
grouped as chronic intestinal pseudo-obstruction syndromes;
and (4) functional intestinal obstruction resulting from mater-
nal infection, maternal intoxication or congenital hypothyroid-
ism.
TREATMENT AND PROGNOSIS
The treatment of HSCR is surgical. After careful preoperative
management, the underlying principle is to place the normal
bowel at the anus and to release the tonic contraction of the
internal anal sphincter. Since the initial protocol of Swenson
described in 1948,4 a series of operative approaches, such as the
Soave and Duhamel procedures, have been developed.23 24 A one
stage procedure is possible when diagnosis is made early, before
colonic dilatation, in short segment disease. Otherwise, a
primary colostomy is required. For long segment disease and
total colonic aganglionosis, temporary enterostomy is often the
first step in management before definitive surgery. Laparoscopic
and transanal pull-through techniques have been proposed more
recently in HSCR surgery.25 These techniques can provide
patients with almost scarless surgery. Comparative long term
results are pending.26 27 Neuronal precursor cells isolated from
the developing human ENS may open the route to cell
therapy.28 29 Fistula or stenosis of the anastomosis and entero-
colitis are the main short term complications.30 Long term
complications include chronic constipation (10–15%) and
soiling.31 32 Mortality has been below 6% since the 1980s and
may be related to short term complications or caused by the
associated malformations.31 However, the treatment of children
with TCA remains hazardous.33 34
EPIDEMIOLOGY
The incidence of HSCR is estimated at 1/5000 live births.5
However, the incidence varies significantly among ethnic
groups (1.0, 1.5, 2.1, and 2.8 per 10 000 live births in
Hispanics, Caucasian-Americans, African-Americans, and
Asians, respectively).15 S-HSCR is far more frequent than
L-HSCR (80% and 20%, respectively).10 12 There is a sex bias
with a preponderance of affected males and a sex ratio of 4/1.35
Interestingly, the male:female ratio is significantly higher for
S-HSCR (4.2–4.4) than for L-HSCR (1.2–1.9) (table 1).15 35
MOLECULAR GENETICS IN ISOLATED HSCR
Several genes have been implicated in isolated HSCR, the two
major ones being RET and EDNRB.
The RET signalling pathway
The first susceptibility locus was mapped to 10q11.2 in
multigenerational families segregating HSCR as an incompletely
penetrant autosomal dominant trait.36 37 This region had been
targeted because of the observation of an interstitial deletion of
chromosome 10q11 in patients with TCA and mental retarda-
tion.38 The proto-oncogene RET (REarranged during
Transfection), identified as disease causing in MEN 239 40 and
mapping in 10q11.2, was regarded as a candidate gene owing to:
(1) co-occurrence of MEN 2A and HSCR in some families; and
(2) expression in neural-crest derived cells. Consequently, RET
gene mutations were identified in HSCR patients (fig 1).41 42
Over 100 mutations have been identified including large
deletions encompassing the RET gene, microdeletions and
insertions, nonsense, missense and splicing mutations.43–46
There is no mutational hot spot at variance with MEN 2A,
where mutations occur in a cluster of six cysteines (exon 10:
residues 609, 611, 618, 620; exon 11: residues 630,634),39 40 47 and
MEN 2B where the mutation is almost unique (M918T, exon
16, tyrosine kinase domain).48–51 In vitro, MEN 2 mutations have
been shown to be activating mutations leading to constitutive
dimerisation of the receptor and to transformation,52 while
haploinsufficiency is the most likely mechanism for HSCR
mutations.53–57 Biochemical studies demonstrated variable con-
sequences of some HSCR mutations (misfolding, failure to
transport the protein to the cell surface, abolished biological
activity).54 56 58 However, a simple activating versus inactivating
model of gene action is not sufficient to explain the co-
occurrence of HSCR and MEN 2A in patients with a MEN 2A
RET gene mutation.51 59
Table 1 Epidemiology and recurrence risk figures in HSCR
L-HSCR S-HSCR
% probands 19 81
Sex ratio (male:female) 1.75 5.5
Genetic model Dominant Multifactorial or recessive
Penetrance (%) (male:female) 52:40 17:4
Recurrence risk to sibs* (%)
Male proband 17/13 5/1
Female proband 33/9 5/3
Relative risk = 200.
*Recurrence risk is given for male/female siblings, respectively.
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Despite extensive mutation screening, a RET mutation is
identified in only 50% of familial and 15–20% of sporadic HSCR
cases.43 44 60 61 However, most families with few exceptions are
compatible with linkage at the RET locus.62 Case–control and
transmission disequilibrium test in several ethnic backgrounds
had first pointed to a frequent SNP lying in exon 2 and leading
to a silent change as over represented and transmitted in
patients (fig 1).63–68 Later, the same observation was made for
haplotypes comprising this SNP lying in exon 2 and an SNP at
–5 from the transcription start site of RET.69–72 As there was no
convincing evidence for a functional role of these two
SNPs,71 73 74 the most likely hypothesis was that an ancient,
low-penetrant founder locus was in linkage disequilibrium with
the haplotype of the two SNPs previously identified and distant
of about 25 kb.70 Comparative genomics focused on conserved
non-coding sequences and an SNP lying in intron 1 was shown
associated to HSCR susceptibility, making a 20-fold greater
contribution to risk than coding sequence mutations.75 This
T.C SNP lies in an enhancer-like sequence and the T allele
reduces in vitro enhancer activity.75 Moreover, this sequence
drives reporter expression in tissue consistent with the one of
Ret during mouse and zebra fish development.75 76 Interestingly,
the frequency of the predisposing T allele varies according to
HSCR prevalence in various ethnic backgrounds from about 20–
50% in European and Chinese, respectively.75 77 The T allele high
frequency in control populations emphasises, as speculated by
the oligogenic model, the pivotal role of the RET gene in HSCR
susceptibility despite low penetrance. Finally, the penetrance of
the T allele for the HSCR trait is both dose-dependent and
greater in males than in females.75 Conversely, an SNP lying in
the 39 UTR of the RET gene and lowering stability to RET
mRNA degradation has been shown to be under transmitted in
HSCR cases.78 Again, this SNP lies on a haplotype that is of
variable frequency according to ethnicity (about 8–4% in
Caucasian and absent in Chinese).71 79 80 A recombination spot
lies on intron 5 at the RET locus.59 66
RET is a 1114 amino acid transmembrane receptor with a
cadherin-like extracellular domain, a cysteine-rich region and a
intracellular tyrosine kinase domain.81 The role of Ret in mice
development has been expanded to kidney,82–84 spermatogen-
esis85–88 and Peyer’s patch.89 90 Between the two RET major
isoforms (RET9 and RET51) with different C-terminal tails as
the result of alternative splicing, RET9 is critical for both kidney
and ENS development.91
GDNF, known as a major survival factor for many types of
neurons, was shown to be the RET ligand by both phenotypic
similarities between Ret 2/2 and Gdnf 2/2 knock-out mice,92–94
and xenopus embryo bioassays.95 GDNF is a TGF-B related 211
residue protein, proteolytically cleaved to a 134 residue mature
protein that homodimerise. To activate RET, GDNF needs the
presence of a glycosylphosphatidylinositol (GPI)-linked co-
receptor GFRA1.96 97 Four related GPI-linked co-receptors,
GFRA1-4,98 and four related soluble growth factor ligands of
RET have been identified, namely: GDNF, NTN,99 persephin
(PSPN)100 and artemin (ARTN).101 Specific combinations of
these proteins are necessary for the development and main-
tenance of both central and peripheral neurons, and all can
signal through RET. GDNF mutations have been identified in
only six HSCR patients to date, and could be regarded as a rare
cause of HSCR (,5%).102–104 Moreover, GDNF mutations may
not be sufficient to lead to HSCR since 4/6 patients have
additional contributory factors, such as RET mutations or
trisomy 21.102 103 Similarly, an NTN mutation has been identified
in one family, in conjunction with a RET mutation.105 Finally,
although Gfra1 homozygous knock-out mice are phenotypically
very similar to Ret and Gdnf 2/2 mice, no GFRA1 mutations
have been identified in HSCR patients except a deletion at the
locus with incomplete penetrance in one family.69 106–109 Worth
noting, RET exerts a pro-apoptotic effect that is inhibited by
GDNF and some RET gene mutations may impair the control of
this activity by GDNF.110
The endothelin signalling pathway
The endothelin pathway was first studied for its vasoconstric-
tive effect and putative role in hypertension. EDNRB and
EDNRA are G-protein-coupled heptahelical receptors that
transduce signals through the endothelins (EDN1, 2, 3).111 112
A susceptibility locus for HSCR in 13q22 was pointed out for
three main reasons: (1) a significant lod-score at 13q22 in a large
inbred Old Order Mennonite community with multiple cases of
HSCR113–115; (2) de novo interstitial deletion of 13q22 in several
patients with HSCR116; (3) synteny between the murine locus
for piebald-lethal (sl), a model of aganglionosis, and 13q22 in
human. The critical role of the endothelin pathway in HSCR
Figure 1 Mutations, haplotypes and
recombination spot at the RET locus.
Review
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was demonstrated with the finding that piebald-lethal was allelic
to the Ednrb knock-out mouse and harboured an Ednrb
mutation (table 2).117 Subsequently, an EDNRB missense
mutation was identified in the Mennonite kindred
(W276C).118 However, the W276C mutation was neither
necessary (affected wild-type homozygotes) nor sufficient
(non-affected mutant homozygotes) to cause HSCR, and
penetrance was sex-dependent (greater in males than in
females).118 piebald-lethal was considered a mouse model for
WS4 in humans, and some of the Mennonite affected
individuals had pigmentary anomalies and sensorineural deaf-
ness in addition to HSCR.113 114 This prompted a screen of the
EDNRB gene in WS4, and homozygous mutations in a fraction
of WS4 families were found.44 At the same time, an Edn3
mutation was identified in the lethal spotting (sl) natural mouse
model for WS4119 and, subsequently, EDN3 homozygote
mutations were identified in WS4 in humans (table 2).120 121
Both EDNRB and EDN3 were screened in large series of
isolated HSCR patients. While EDN3 mutations were seldom
found,130 EDNRB mutations were identified in approximately
5% of the patients.126–129 It is worth mentioning that the
penetrance of EDN3 and EDNRB heterozygous mutations is
incomplete in those HSCR patients, de novo mutations have
not hitherto been observed, and that S-HSCR is largely
predominant. Interstitial 13q22 deletions encompassing the
EDNRB gene in HSCR patients makes haploinsufficiency the
most likely mechanism for HSCR (table 3). Although EDNRB
binds all three endothelins, the similarity of phenotype of the
Ednrb knock-out mice to that of the Edn3 knock-out mice
suggests that EDNRB’s major ligand is EDN3.
Preproendothelins are proteolytically cleaved by two related
membrane-bound metalloproteases to give rise to the mature
21-residue endothelin. Ece1 processes only Edn1 and Edn3. Ece1
knock-out mice show craniofacial defects and cardiac abnorm-
alities in addition to colonic aganglionosis.132 A heterozygous
ECE1 mutation has been identified in a single patient combining
HSCR, craniofacial and cardiac defects (R742C).131
SOX10
The last known mouse model for WS4 in human is dominant
megalon (Dom), homozygous Dom mutation being embryonic
lethal.152 The Dom gene is Sox10, a member of the SRY (sex
determining factor)-like, high mobility group (HMG) DNA
binding proteins.125 Subsequently, truncating heterozygote
SOX10 mutations have been identified in patients with
WS4,122–124 Yemenite deaf-blind-hypopigmentation syndrome153
and WS2 (Bondurand et al in Am J Hum Genet website) but also
in patients presenting in addition neurological impairment due
to central and peripheral dysmyelination.67 123 The latter
combination is known as PCWH for Peripheral demyelination-
Central dysmyelinating leucodystrophy-Waardenburg syn-
drome and Hirschsprung disease. Genotype–phenotype correla-
tion relies on nonsense-mediated decay being effective (WS4) or
not (PCWH).154 The penetrance of the HSCR trait appears to be
high, although sibs sharing a mutation and discordant for HSCR
have been described in one family.124 Therefore, SOX10 is
unlikely to be a major gene in isolated HSCR.
Interaction between pathways
Ret and Ednrb signalling pathways were considered biochemi-
cally independent. However, G-protein-coupled receptors and
tyrosine kinase receptors could be engaged in crosstalk.
Moreover an HSCR patient heterozygote for weak hypo-
morphic mutations in both RET and EDNRB has recently been
reported.155 Each mutation was inherited from a healthy parent.
Genetic interactions between EDNRB and RET have been
demonstrated in the Mennonite population where HSCR
predisposition is high (incidence of 1/500).118 156 Finally, no
complementation of aganglionosis could be observed in mouse
Table 2 Genes involved in HSCR in humans and known mouse models of megacolon
Gene
Human Mouse
Map
location
Mode of
inheritance
Phenotype in
mutants Penetrance of the HSCR trait Refs
Natural
mutant Knockout Refs
RET 10q11.2 AD HSCR 70% in males and 50% in females
for CDS mutations
43, 44, 60, 61 – L
Renal agenesis
82
GDNF 5p13 AD HSCR 5 cases reported
Low penetrance
102–104 – L 92–94
Renal agenesis
NTN 19p13 AD HSCR 1 case reported 105 – –
SOX10 22q13 AD WS4 About 80% 122–124 Dom (AD) L
Coat spotting
125
EDNRB 13q22 AR/AD WS4/HSCR Low 118, 126–129 sl (AR) S
Coat spotting
117
EDN3 20q13 AR/AD WS4/HSCR 1 case reported 130 ls (AR) S
Coat spotting
119
ECE1 1p36 AD HSCR 1 case reported 131 – S
Coat spotting
Craniofacial defects
132
CF and cardiac
defect
ZFHX1B (SIP1) 2q22 AD MCA-MR, facial
gestal,
60% 133–135 – Letal at gastrulation 136
PHOX2B 4p12 AD CCHS 20% 137, 138 – TIA
No ANS
Ventilatory anomalies
in Phox2b+/2
139, 140
TCF4 18q21 AD Epileptic
encephalopathy
1 case 141–143 – Early letality
Abnormal maturation
of lymphocytes
144, 145
AD, autosomal dominant; ANS, autonomic nervous system; AR, autosomal recessive; CF, craniofacial; L, long-segment megacolon; MR, mental retardation; S, short-segment
megacolon; Spo, sporadic; sl, Piebald lethal; ls, lethal spotting; TIA, total intestinal aganglionosis.
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inter crosses between hypomorphic piebald alleles of Ednrb
(Ednrbs/s) and a null allele of Ret.156
Sox10 is involved in cell lineage determination and is capable
of transactivating MITF synergistically with PAX3.157 Similarly,
Ednrb transcripts are either absent or drastically reduced in
Dom2/2 and Dom+/2 mice, respectively.158 Sox10;Ednrb and
Sox10;Edn3 double mutants have a severe ENS defect with no
enteric progenitor cells extending beyond the stomach at all
embryonic stages studied.159 Interestingly, genetic interactions
for the HSCR trait have been shown between RET and PHOX2B
and BBS genes responsible when mutated for CCHS and Bardet-
Biedl syndromes, respectively.148 Such correlation was not found
between RET and SOX10. Along these lines, a genome-wide
screen aimed at localising modifier genes for the aganglionosis of
Dom mice did not point to the Ret locus but, among others, a
locus encompassing the PHOX2b gene.160
Taking it all together, several general comments can be made:
(1) RET is the major gene in HSCR with either CDS mutations
or, more frequently, a low penetrant SNP lying in an enhancer
element within intron 1; (2) RET mutation penetrance is
incomplete and sex-dependant; (3) genotype–phenotype corre-
lation is poor; 4) HSCR is genetically heterogeneous and due to
mutations in distinct pathways; (5) some patients with
mutations in more than one HSCR susceptibility gene are
known (RET+GDNF, RET+NTN, RET+EDNRB); (6) the RET
gene plays a role in HSCR penetrance of some but not all
syndromic HSCR (see below).
MULTIGENIC INHERITANCE OF ISOLATED HIRSCHSPRUNG
DISEASE
As mentioned above, RET plays a key role in HSCR genesis and
multiple genes may be required to modulate clinical expression.
On the other hand, genetic heterogeneity where mutation in
one of several genes is sufficient for phenotypic expression of
HSCR has been demonstrated (RET, EDNRB, EDN3, ECE1).
Segregation studies in HSCR showed that the recurrence risk in
siblings varies from 1.5–33% depending on the gender and the
length of the aganglionic segment in the proband, and the
gender of the sibling (table 1).5 35 Consequently, HSCR has been
assumed to be a sex modified multifactorial disorder, the effect
of genes playing a major role as compared to environmental
factors (relative risk of 200).
According to the segregation analysis where an autosomal
dominant model in L-HSCR and a multifactorial model in S-
HSCR were more likely, different approaches have been chosen
to test these hypotheses in L-HSCR and S-HSCR independently.
a. Linkage analysis in 12 HSCR families with three or more
affected individuals in two or more generations where L-
HSCR is largely predominant.62 All but one family showed
linkage to the RET locus. Mutational analysis identified a
nonsense or missense mutation at highly conserved residue
in six families, a splice mutation in two families and no
coding sequence variation in three families. Linkage to a
novel locus in 9q31 was identified only in families with no
or hypomorphic RET gene mutation. Therefore, a severe
RET mutation may lead to phenotypic expression by
haploinsufficiency while hypomorphic RET mutations
would require the action of other mutations.
b. A sib-pair analysis in 49 families with S-HSCR probands.161
This studies shows that only three loci on chromosomes
3p21, 10q11 and 19q12 are both necessary and sufficient to
explain the incidence and sibling recurrence risk in HSCR. A
multiplicative risk across loci with most affected individuals
being heterozygotes at all three loci seems the best genetic
model. Finally, linkage to 9q31 was confirmed in the sib-
pairs with no or hypomorphic RET mutation.
c. A genome-wide association study was conducted in 43
Mennonite family trios and identified a susceptibility locus
on 16q23 in addition to the loci of the two predisposing
genes in this population (RET and EDNRB at 10q11.2 and
13q22, respectively).156
d. Linkage analysis in a multigenerational HSCR family where
the RET gene had been previously excluded, showed linkage
to 4q31-q32.162
The route to the identification of modifier genes is now based
on various approaches. A differential screen for ENS expressed
genes was conducted by a 22 000 probe DNA micro array of
embryonic Ret+/+ and Ret2/2 mice and identified over 300 genes
over expressed in Ret+/+ mice.29 These genes are regarded as
critical for enteric neurogenesis and therefore potential candi-
dates in HSCR. By synteny, some lie at candidate modifier loci
for isolated HSCR. Other approaches undertook by the HSCR
Consortium are microarrays of RNAs from microdissection of
enteric neurons and glia on the one hand and 500 k SNP
genotyping in trios on the other hand.
SYNDROMIC HSCR
HSCR occurs as an isolated trait in 70% of cases. A
chromosomal abnormality is associated in 12% of cases, trisomy
21 being by far the most frequent (.90%). Associated
congenital anomalies are found in 18% of the HSCR patients.
The one occurring at a frequency above that expected by chance
include gastrointestinal malformation, cleft palate, polydactyly,
cardiac septal defects and craniofacial anomalies.13 14 The higher
rate of associated anomalies in familial cases than in isolated
cases (39% vs 21%) strongly suggests syndromes with
Mendelian inheritance.14 Assessment of all HSCR patients by
a trained dysmorphologist should provide a careful evaluation
for recognisable syndromes.
Table 3 Recurrent chromosomal anomalies with HSCR as a feature
Chromosome Key features Number of reports Gene References
Tri 21 Down syndrome, S-HSCR, 5.5 to 10.5 male: female sex ratio 2–10% of HSCR cases ? 5, 11–15
Del 10q11 Mental retardation, L-HSCR 2 cases RET 38, 146
Del 13q22 Mental retardation, growth retardation, dysmorphic features, S-HSCR .10 cases EDNRB 116
Del 2q22-q23 Postnatal growth retardation and microcephaly, mental retardation, epilepsy,
dysmorphic features, HSCR*
.10 cases ZFHX1B 133–135, 147, 148
Del 17q21 .1 case ? 149
Dup 17q21-q23 MCA/MR 4 cases ? 150
Tri 22pter-q11 Cat eye syndrome ? 151
*Both S-HSCR and L-HSCR have been observed.
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Chromosomal anomalies
A large number of chromosomal anomalies have been described
in HSCR patients. Free trisomy 21 (Down syndrome) is by far
the most frequent, involving 2–10% of ascertained HSCR
cases.5 11–15 In these cases, both the unbalanced sex ratio (5.5–
10.5:1 male:female) and the predominance of S-HSCR are even
greater than in isolated HSCR. Over-expression of gene(s) on
chromosome 21 and predisposing to HSCR has been hypothe-
sised and a susceptibility gene mapping to 21q22 postulated in a
Mennonite kindred.114 However, these data were not con-
firmed.156 Hitherto, coding sequence mutations in genes predis-
posing to HSCR, RET, EDNRB and GDNF, respectively, were
found in only three patients with Down syndrome and
HSCR.103 163 However, the common HSCR predisposing RET
hypomorphic allele is over represented in patients with Down
syndrome and HSCR when compared to patients without
HSCR.148
Some chromosomal interstitial deletions reported in combi-
nation with HSCR, have been important for the identification
of HSCR predisposing genes, namely: (1) 10q11.2 interstitial
deletion observed in a few patients with L-HSCR or TCA38 146
leading to the mapping and identification of the first HSCR
predisposing gene (RET); (2) 13q22.1-32.1 interstitial deletion in
patients with S-HSCR leading to the mapping of the second
gene (EDNRB)164–166; (3) 2q22-23 interstitial deletion syndrome
in patients with a multiple congenital anomaly–mental
retardation (MCA-MR) syndrome with HSCR or severe chronic
constipation further delineated as Mowat-Wilson syndrome
(table 3),133 134 147 leading to the identification of the ZFHX1B
gene (previously named SIP1 gene).135
Rarer chromosomal anomalies reported in combination with
HSCR are summarised in table 3. DiGeorge syndrome, mosaic
trisomy 8, XXY chromosomal constitution, partial duplication
of chromosome 2q, tetrasomy 9p, and 20p deletion, have been
observed at least once with HSCR. Interestingly, a patient with
S-HSCR, postnatal growth retardation, mild developmental
delay, dysmorphic facial features and a deletion at 4p12
encompassing the PHOX2B gene has been reported.167
Syndromes and associated anomalies
Both the recognition of known entities and the delineation of
novel ones including HSCR as a feature are of importance for
disease prognosis, accurate genetic counselling and search for
candidate genes. Syndromes reported associated with HSCR are
numerous. Some associations are well characterised with a
penetrance of HSCR ranging from 5% to .80% (table 2). For
rare disorders, whether an association with HSCR observed
once is meaningful or occurred by chance alone is not possible to
decide. These conditions are summarised in table 4. Both
frequent and occasional associations may be of interest for the
identification of susceptibility genes to HSCR.
Syndromes frequently associated with HSCR: neurocristopathies
The NC is a transient and multipotent embryonic structure that
gives rise to neuronal, endocrine and paraendocrine, craniofacial,
conotruncal heart and pigmentary tissues.7 Neurocristopathies
encompass tumours, malformations and single or multifocal
anomalies of tissues mentioned above with various combina-
tions. MEN 2, neuroblastoma (NB) conotroncal heart defects
and Waardenburg syndromes illustrate each of these categories,
and are associated with HSCR.
Multiple endocrine neoplasia type 2 and familial medullary thyroid
carcinoma
Familial medullary thyroid carcinoma (FMTC), MEN type 2A
(MEN 2A) and type 2B (MEN 2B) are cancer predisposition
syndromes with an autosomal dominant mode of inheritance.
MEN 2A is defined by an age-related predisposition to
medullary thyroid carcinoma (MTC, 70% by the age of 70
years), pheochromocytoma (50% of cases) and hyperplasia of
the parathyroid glands (15–35%). In addition to MTC and
pheochromocytoma, individuals with MEN 2B present with
oral neuromas, marfanoid habitus and hyperganglionosis of the
hindgut.208 Germline missense mutations of the RET gene have
been identified in MEN 2A, MEN 2B and FMTC. Both FMTC
and MEN 2A can be associated with HSCR in some
families.47 175–181 Interestingly, these families present a germline
RET mutation of the MEN 2A or FMTC type (see below).47 176–181
This raises the question of whether all individuals with HSCR,
regardless of non-contributive family history, should be
screened for RET exon 10 and 11 mutations to rule out cancer
predisposition (3/160 cases in our series with C609W, C611R
and C620R RET gene mutations, respectively).
Neuroblastoma
Neuroblastoma (NB) is the most frequent solid tumour in
childhood with an incidence of 1/10 000. The tumour can arise
at any site of the sympathetic chain or the adrenal medulla
(both originating from NCC). In some families, tumour
predisposition segregates through generations with incomplete
penetrance.209–211 NB is found associated to HSCR and con-
genital central hypoventilation (CCHS, see below) in various
combinations and, in each combination, heterozygous muta-
tions of the paired-like homeobox 2B gene (PHOX2B) have been
identified.137 212–217 However, germeline PHOX2B mutations
remain rare in sporadic, isolated NB.215 216
Congenital central hypoventilation syndrome (CCHS, MIM 209880).
Initially termed Ondine’s curse, CCHS is a rare, life-threatening
condition characterised by abnormal ventilatory response to
hypoxia and hypercapnia due to failure of autonomic respira-
tory control.218 CCHS is not per se a neurocristopathy due to the
involvement of both the central and peripheral autonomic
nervous system. CCHS patients often present symptoms
resulting from a broader dysfunction of the autonomous
nervous system and predisposition to neural crest cell derived
tumours (5–10% of CCHS cases, neuroblastoma, ganglioblas-
toma, ganglioneuroma).209 219–221 Haddad syndrome (MIM
209880) is defined by the association of HSCR and CCHS and
is found in about 20% of CCHS patients.138 172 173 In these cases,
L-HSCR (including TCA) is the most frequent, and the sex ratio
is almost equal at variance to what is observed in isolated
HSCR.222 PHOX2B is the disease causing gene with de novo
heterozygous mutation in the proband,174 the far most frequent
being in frame duplication leading to polyalanine expan-
sion.223 224 Parents of patient with molecularly proven CCHS
must be tested for accurate genetic counselling as about 10%
carry a somatic mosaic137 and some parents may develop late
onset CHS.225 Finally, genotype/phenotype correlations allow
the detection of patients with a high risk to develop tumours
(and carry a frameshift mutation) and reassurance about
tumour predisposition to those carrying a polyalanine expan-
sion.137
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Waardenburg syndromes (WS) and related pigmentary anomalies
WS, an autosomal dominant condition, is by far the most
frequent condition combining pigmentary anomalies and
sensorineural deafness (1/50 000 live births and 2–5% of all
congenital deafness), resulting from the absence of melanocytes
of the skin and the stria vascularis of the cochlea.226 WS is
clinically and genetically heterogeneous (MIM 193500, MIM
148820, MIM 193510).227 The combination of HSCR with WS
defines the WS4 type (Shah-Waardenburg syndrome, MIM
277580), a genetically heterogeneous condition. Indeed, homo-
zygous mutations of the endothelin pathway118 120 121 168 and
heterozygous SOX10 mutations have been identified in WS4
patients.122 Patients carrying a SOX10 mutation may also
present with CNS involvement including seizures, ataxia, and
demyelinating peripheral and central neuropathies123 228 and
WS2 (Bondurand et al in Am J Hum Genet website).
Related syndromes associating pigmentary anomalies and
HSCR include: (1) Yemenite deaf-blind hypopigmentation
syndrome (MIM 601706), a SOX10 mutation having been
reported in one of these families153; (2) Black Locks-Albinism-
Deafness syndrome (BADS, MIM 227010) with TCA-HSCR in
one case169; (3) aganglionic megacolon associated with familial
piebaldism (MIM 172800)170 171; (4) HSCR and profound
congenital deafness but with no other WS features has also
been reported.229
Other neurocristopathies
Familial dysautonomia syndrome (FDS, Riley-Day syndrome,
MIM 223900) has been reported once in association with HSCR.
Although it could have arisen by chance alone, it is interesting
to note that FDS maps to 9q31 where a susceptibility locus for
HSCR has been identified. Other occasional associations
Table 4 Syndromes associated with HSCR
Syndromes MIM Key features References
Syndromic NCC
disorders
WS4 (Shah-Waardenburg) 277580 Pigmentary anomalies (white forelock, iris hypoplasia, patchy hypopigmentation) 118, 120–122, 168
Yemenite deaf-blind-
hypopigmentation
601706 Hearing loss, eye anomalies (microcornea, coloboma, nystagmus), pigmentary anomalies 153
BADS 227010 Hearing loss, hypopigmentation of the skin and retina 169
Piebaldism 172800 Patchy hypopigmentation of the skin 170, 171
Haddad 209880 Congenital central hypoventilation 172–174
MEN2A Medullary thyroid carcinoma, pheochromocytoma, hyperplasia of the parathyroid 47, 175–181
Riley-Day 223900 Autonomic nervous system anomalies
HSCR mandatory Goldberg-Shprintzen 235730 Mental retardation, polymicrogyria, microcephaly, CF, coloboma, facial dysmorphic
features
182–184
HD with limb anomalies 235740 Polydactyly, unilateral renal agenesis, hypertelorism, deafness 185
235750 Postaxial polydactyly, ventricular septal defect 186
235760 Hypoplasia of distal phalanges and nails, dysmorphic features 187
604211 Preaxial polydactyly, heart defect, laryngeal anomalies 188
306980 Brachydactyly type D 189
BRESHEK Brain abnormalities , Retardation, Ectodermal dysplasia, Skeletal malformation,
Hirschsprung disease, Ear/eye anomalies, Kidney dysplasia
190
Mowat-Wilson 235730 Mental retardation, microcephaly, epilepsy, facial gestalt, hypospadias, renal anomalies,
ACC, CCD
135, 148, 191–193
HSCR
occasionally
associated
Bardet-Biedl syndrome and/or 209900 Pigmentary retinopathy, obesity, hypogenitalism, mild mental retardation, postaxial
polydactyly
194, 195
Kauffman-McKusick 236700 Hydrometrocolpos, postaxial polydactyly, congenital heart defect 196
Smith-Lemli-Opitz 270400 Growth retardation, microcephaly, mental retardation, hypospadias, 2–3 toes syndactyly,
dysmorphic features
197
Cartilage-hair hypoplasia 250250 Shortlimb dwarfism, metaphyseal dysplasia immunodeficiency 198
HSAS/MASA 307000 Hydrocephalus, aqueductal stenosis, spasticity adducted thumbs, ACC, mental retardation 199
HSCR rarely
associated
Fukuyama congenital muscular
dystrophy
253800 Muscular dystrophy, polymicrogyria, hydrocephalus, MR, seizures 200, 201
Clayton-Smith 258840 Dysmorphic features, hypoplastic toes and nails, ichthyosis 202
Kaplan 304100 Agenesis of corpus callosum, adducted thumbs, ptosis, muscle weakness 203
Okamoto 308840 Hydrocephalus, cleft palate corpus callosum agenesia 204
Werner mesomelic dysplasia 188770 205, 206
Pitt-Hopkins 610954 Epileptic encephalopathy, facial dysmorphic features, bouts of hyperventilation,
dysautonomia
141–143
Jeune asphyxing thoracic
dystrophia
208500 207
Miscellaneous
associations
Pallister-Hall (CAVE) 140510
Fryns 229850
Aarskog 100050
Fronto-nasal dysplasia 136760
Osteopetrosis
Goldenhar 164210
Lesch-Nyhan 308000
Rubinstein-Taybi 180849
Toriello-Carey 217980
SEMDJL 271640
Adapted from: Scriver CM et al. The metabolic and molecular bases of inherited diseases. 8th ed. McGraw-Hill, pp 6231-55.
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reported thus far include cleft lip with or without cleft palate,230
neural tube defects (myelomeningocoele)231 and neurofibroma-
tosis type I.210 The significance of these associations is not yet
established.
Other syndromes with HSCR as a frequent feature
Mowat-Wilson syndrome (MIM 235730)
Mowat-Wilson syndrome (MWS) is an MCA-MR condition
first delineated among the heterogeneous group of patients with
HSCR and MR.134 The condition is associated with micro-
cephaly, epilepsy, a facial gestalt and severe mental retardation.
The spectrum of possibly associated malformations is wide and
encompasses, in decreasing frequency order, hypospadias, renal
anomalies, congenital cardiac defect, agenesis/hypoplasia of the
corpus callosum and HSCR.148 193 Heterozygous de novo dele-
tions encompassing the ZFHX1B (zinc finger homeo box 1B)
gene or truncating mutations within the gene are found in over
100 cases.135 191 192 Some rare splicing and missense mutations
have also been reported.148 Loss of function by haploinsuffi-
ciency is the disease causing mechanism in humans. ZFHX1B
acts as a transcriptional repressor of smad protein targets and
has key functions in early embryonic development in several
animal models.94 136 232 A knock-out restricted to NCC precursors
in mice demonstrated a wide range of anomalies in NCC
derivatives.233
Goldberg-Shprintzen syndrome (MIM 609460).
This autosomal recessive MCA-MR syndrome combines HSCR,
moderate mental retardation, microcephaly, polymicrogyria,
facial dysmorphic features (hypertelorism, prominent nose,
synophrys, sparse hair), cleft palate and iris coloboma.182 183
The disease causing gene KIAA1279 has been identified in a
large consanguineous family and encodes a protein of unknown
function.184 GSS is a rare condition within the group of patients
with MR and HSCR. Several reports with variable association of
microcephaly, iris coloboma, cleft palate and mental retarda-
tion, and regarded as possible variants GSS, are unlikely allelic
conditions.234 235
HSCR with limb anomalies
Several rare syndromes with HSCR and distal limb anomalies
(polydactyly or hypoplasia) have been reported. These are: (1)
HSCR with polydactyly, unilateral renal agenesis, hypertelor-
ism and congenital deafness (MIM 235740)185; (2) HSCR,
postaxial polydactyly and ventricular septal defects (MIM
235750)186; (3) HSCR, hypoplasia of the distal phalanges and
nails and mild dysmorphic features (MIM 235760)187; (4) HSCR
with preaxial polydactyly, heart defect and laryngeal anomalies
(MIM 604211)188; (5) HSCR with brachydactyly type D (MIM
306980)189; (6) HSCR with brachydactyly, macrocephaly and
vertebrae anomalies190; (7) BRESHEK syndrome236; and (8)
Werner mesomelic dysplasia.205 206
Bardet-Biedl syndrome (MIM 209900) and McKusick-Kauffman
syndrome (MIM 236700)
Bardet-Biedl syndrome (BBS) is characterised by progressive
pigmentary retinopathy, obesity, hypogenitalism, renal involve-
ment (including cysts, renal cortical loss or reduced ability to
concentrate urine), mild mental retardation and postaxial
polydactyly of the hands and feet. BBS is genetically hetero-
geneous with at least 12 loci and 10 genes identified, all involved
in ciliary function.237 HSCR has been reported in several BBS
cases.194 195 McKusick-Kauffman syndrome (MKKS) is a rare
condition, allelic to BBS and characterised by hydrometrocolpos,
postaxial polydactyly and congenital heart defect. HSCR is
found in 10% of cases.196 Mutations in the MKKS/BBS6 gene,
encoding a chaperonin protein, were identified in some BBS
patients confirming that both conditions are allelic.238 239 Jeune
syndrome, also ascribed to a gene involved in the ciliary
function, has been occasionally associated to HSCR.207
Smith-Lemli-Opitz syndrome (MIM 270400)
Smith-Lemli-Opitz syndrome (SLO) is characterised by pre- and
postnatal growth retardation and microcephaly, severe mental
retardation, facial dysmorphic features, hypospadias and syn-
dactyly between toes 2 and 3. SLO results from cholesterol
metabolic impairment with mutation of the 7-dehydro-choles-
terol reductase gene (DHCR7, chromosome 11q12-q13).240 241
HSCR is observed in a significant number of severe SLO
patients.197
Cartilage-hair hypoplasia syndrome (MIM 250250)
The skeletal dysplasia cartilage-hair hypoplasia syndrome
(CHH), first described in the Old Order Amish community,
combines metaphyseal dysplasia with short limb dwarfism,
fine, sparse and blond hair, transient macrocytic anaemia and
immunodeficiency. HSCR is associated in approximately 10% of
the cases.198 The gene RMRP has been mapped to chromosome
9p13.242 Interestingly, HSCR has been reported in the
Holmgren-Connor syndrome (MIM 211120) which may be
allelic to CHH.
The RET gene plays a pivotal role in both isolated and
syndromic HSCR. Indeed, epistatic interactions with the
common RET hypomorphic allele has been demonstrated for
HSCR predisposition in Down, CCHS and BBS.148 243
Conversely, the role of the RET hypomorphic allele is not
significant in MWS and WS4 due to SOX10 mutation.148 Of
note, a case–control study in a Chinese population identified an
SNP in intron 2 of PHOX2B (IVS2+100) as over represented in
the HSCR group of patients.244
Miscellaneous observations
This can be include; (1) syndromes with myopathy200 201; (2)
syndromes with dermatological findings202; and (3) syndromes
with central nervous system anomalies, among which the
HSAS/MASA spectrum ascribed to mutations in the X-linked
L1CAM gene. Indeed, at least five different mutations in
L1CAM have been identified in patients with hydrocephalus
and HSCR.199 Interestingly, L1cam is an ENS-expressed gene.29
The question of L1CAM being a modifier gene in HSCR has
been raised with no definitive answer given thus far.245 246 Other
rare associations include the finding of HSCR with Fryns,
Aarskog, Jeune asphyxing thoracic dystrophia, Joubert, fronto-
nasal dysplasia, osteopetrosis, Goldenhar, Lesch-Nyhan,
Rubinstein-Taybi, Toriello-Carey, Pallister-Hall, spondylo-epi-
metaphyseal dysplasia with joint laxity (SEMDJL, MIM
271640), persistent mullerian duct syndromes, and asplenia
with cardiovascular anomaly.
Associated anomalies
A wide spectrum of additional isolated anomalies have been
described among HSCR cases, with an incidence varying from
5–30% according to series.10 11 13 247–250 No constant pattern is
observed and these anomalies include distal limb, sensorineural,
skin, central nervous system, genital, kidney and cardiac
malformations. However, cardiac defects, and mostly atrio- or
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ventriculoseptal defects, are found with an incidence of 5% of
HSCR cases, once removed patients with trisomy 21 and HSCR.
Renal dysplasia or agenesis was reported in FMTC251 and found
in 4.4% in a series of 160 HSCR cases and may still be
underestimated (personal data). This is of interest since
homozygous knock-out mice for genes involved in the Ret
signalling pathway present with renal agenesia/dysplasia in
addition to megacolon.82 Genital anomalies including hypospa-
dias are reported in up to 2–3% of HSCR patients.
Gastrointestinal malformations such as Meckel diverticulum,
pyloric stenosis, single umbilical arteria, inguinal hernia or small
bowel atresia are also found.252–254 Finally, facial dysmorphic
features seem extremely frequent when looked for. These data
highlight the importance of a careful assessment by a clinician
trained in dysmorphology for all newborns diagnosed with
HSCR. Skeletal x ray, cardiac and urogenital ultrasound survey
should be systematically performed. The observation of one
additional anomaly to HSCR should prompt chromosomal
studies and/or molecular karyotyping.
The unanswered question of sex-dependent penetrance in HSCR
Expression and penetrance of a RET mutation is variable and
sex-dependent within HSCR families. In large series, the
estimated penetrance is 72% in males and 51% in females.44
Accordingly, the penetrance of the HSCR predisposing T allele
for the HSCR trait is greater in females than in males.75 A
significant parent-of-origin effect at the RET locus, 78% of
shared RET alleles by affected sibs being maternally derived,
could explain the sex difference in HSCR expression. Epigenetic
effects at the RET locus have been hypothesised. Of note, a sex
difference in disease expressivity (that is, length of the
aganglionic segment) of Ret+/2; Ednrbs/s mice has been
observed.255 None of the genome wide scans performed in
HSCR families identified a locus on the X chromosome thus far.
However, a differential screen for ENS expressed genes
performed in mice pointed to several X-linked genes.29 Finally,
the observation of a skewed sex ratio in RET-independent
syndromic HSCR (that is, MWS and WS4) suggests that the sex
bias observed cannot entirely rely on a gender effect at the RET
locus.148
GENETIC COUNSELLING
HSCR is a sex-modified multifactorial congenital malformation
with an overall recurrence risk in sibs of the proband of 4%
(relative risk = 200). In isolated HSCR, adequate relative risk
figures will be provided by taking into account the sex and
length of the aganglionic segment in the proband and the gender
of the sibling (2–33%). According to Carter’s paradox, the
highest recurrence risk is for a male sibling of a female proband
with L-HSCR (table 1). According to poor genotype–phenotype
correlation thus far, the benefit of mutation screening for HSCR
patients appears low except for systematic testing of exon 10
and 11 of the RET gene, owing to cancer predisposition of
MEN2A mutations. This, however, is still not routine practice
in most countries.
Many HSCR cases are associated with other congenital
anomalies. In these cases, the long term prognosis is highly
dependent on the severity of the associated anomalies. Several
known syndromes have straight Mendelian inheritance. This
emphasises the importance of careful assessment by a clinician
trained in syndromology of all newborns diagnosed with HSCR.
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